Which Antidepressants Cause High Blood Sugar?

Several classes of antidepressants have been linked to elevated blood sugar, but the picture is not as simple as a single blacklist. A large systematic review in Diabetes Care found that some antidepressants worsen glucose control while others actually improve it, and the risk tends to climb with higher doses and longer use. Tricyclic antidepressants and certain individual SSRIs and SNRIs carry the clearest signals, while drugs like bupropion appear to nudge blood sugar in the opposite direction. The details matter because depression and diabetes frequently overlap, and picking the wrong antidepressant can quietly make metabolic problems worse.

The Overall Link Between Antidepressants and Blood Sugar

Across many large studies, antidepressant use as a broad category is associated with a modestly higher risk of developing type 2 diabetes. A Japanese cohort study of over 90,000 people found that the risk rose in a dose- and time-dependent fashion: people on short-term, low-dose antidepressants had roughly a 27 percent higher chance of developing diabetes, while those on long-term, high-dose regimens faced nearly four times the risk compared with non-users.¹ That dose-response pattern is one of the stronger pieces of evidence that the drugs themselves play a role, rather than the association being entirely explained by depression or lifestyle.

A separate systematic review confirmed that the overall association exists but emphasized a messy reality: some antidepressants are linked to worsening glucose control, others to improved control, and still others show mixed results depending on the study.² So “antidepressants raise blood sugar” is too blunt. The real question is which ones, through what pathways, and how much the risk depends on dose and duration.

Tricyclic Antidepressants

Older tricyclic antidepressants (TCAs) carry some of the most consistent evidence for disrupting blood sugar. In animal studies, nortriptyline significantly raised glucose levels while simultaneously lowering insulin, a combination that points to direct interference with insulin secretion or sensitivity.³ Case reports have also flagged imipramine and clomipramine for hyperglycemia in clinical use.⁴

The likely reasons trace back to how TCAs interact with multiple receptor systems. They block histamine receptors, which promotes weight gain. They also affect norepinephrine reuptake, and an analysis of spontaneous adverse-event reports found that the strongest associations with hyperglycemia involved antidepressants with affinity for the histamine-1 receptor and the norepinephrine reuptake transporter.⁵ TCAs tend to check both of those boxes. Add in the well-known weight gain many people experience on drugs like amitriptyline, and you have a recipe for gradually worsening insulin resistance.

TCAs are prescribed far less often now than they were a few decades ago, partly because newer drugs have fewer side effects overall. But they still see use for chronic pain, migraines, and treatment-resistant depression, which means the blood sugar risk remains relevant for anyone taking them long-term.

SSRIs Have a Complicated Track Record

Selective serotonin reuptake inhibitors are the most widely prescribed antidepressants in the world, and their relationship with blood sugar is genuinely mixed. As a class, SSRIs have been linked to a modest increase in type 2 diabetes risk. A large study of children and adolescents on public insurance found that starting an SSRI was associated with a 13 percent increase in the hazard of developing type 2 diabetes, and the risk rose to 33 percent among those who stayed on the drug continuously.⁶

But individual SSRIs behave differently. Fluoxetine, the oldest and one of the most commonly prescribed, has lab evidence suggesting it impairs how pancreatic beta cells secrete insulin in response to glucose. It appears to disrupt calcium signaling inside those cells, which is a core step in the insulin release process.⁷ That finding matters because fluoxetine is widely considered weight-neutral or even mildly weight-reducing, so clinicians sometimes assume it is metabolically safe. The blood sugar story may be more nuanced than the weight story.

Escitalopram, by contrast, has shown signs of actually lowering fasting blood sugar in clinical studies, despite being associated with increases in waist circumference and cholesterol.⁸ That same study found no significant changes in blood sugar or body measurements with fluoxetine, sertraline, or venlafaxine over the treatment period. Animal research has even shown that escitalopram can reverse insulin resistance in certain stress-related models by calming down the body’s stress-hormone axis.⁹

Sertraline and paroxetine add yet another wrinkle. Lab work on isolated pancreatic islets showed that both drugs enhanced glucose-stimulated insulin secretion and even protected beta cells from damage caused by inflammatory signals.¹⁰ Yet both sertraline and paroxetine also appear in clinical case reports of hyperglycemia.⁴ The disconnect probably reflects the difference between a direct effect on insulin-producing cells and the overall metabolic impact that includes weight gain, changes in appetite and activity, and shifts in stress hormones. A drug can be good for beta cells in a dish and still push blood sugar up in a real person who gains fifteen pounds over a year.

SNRIs and the Norepinephrine Factor

Serotonin-norepinephrine reuptake inhibitors like venlafaxine and duloxetine add norepinephrine reuptake inhibition on top of serotonin effects. An older review concluded that these dual-mechanism drugs do not appear to disrupt glucose balance.¹¹ But more recent data challenges that reassurance. A study comparing short-term diabetes risk across antidepressant classes found that SNRIs, not SSRIs, were the ones that raised the risk of developing type 2 diabetes within the first year of use when compared with fluoxetine as a reference.¹²

The norepinephrine component is the likely culprit. Norepinephrine signals the liver to release stored glucose and can reduce insulin sensitivity, both of which push blood sugar up. The spontaneous-report analysis mentioned earlier found that affinity for the norepinephrine transporter was one of the receptor-level features most strongly tied to hyperglycemia reports.⁵ Duloxetine is sometimes prescribed specifically for diabetic nerve pain, which creates an uncomfortable irony: the drug treating a diabetes complication may contribute to worsening blood sugar control in some patients.

Mirtazapine and Other Atypical Antidepressants

Mirtazapine stands out among atypical antidepressants for its strong antihistamine effects, which translate into increased appetite, weight gain, and sedation. It has been reported in case analyses to cause hyperglycemia.⁴ Its receptor profile hits the same targets identified as problematic for blood sugar: high affinity for the histamine-1 receptor and the serotonin 5-HT2c receptor.⁵ The 5-HT2c receptor influences appetite regulation and energy metabolism, and blocking it tends to increase food intake. For someone already at risk for diabetes, the combination of increased appetite, weight gain, and direct metabolic effects makes mirtazapine a drug worth monitoring closely.

Bupropion occupies a more favorable position. Unlike most other antidepressants, it works primarily through dopamine and norepinephrine pathways and does not cause weight gain. In fact, when combined with naltrexone in a formulation for weight management, it produced meaningful improvements in blood sugar control among overweight and obese people with type 2 diabetes, including a significantly greater reduction in HbA1c compared with placebo.¹³ That result is partly driven by the weight loss the combination produces, but it still positions bupropion as one of the more metabolically friendly antidepressant choices for people worried about blood sugar.

When Add-On Medications Muddy the Picture

People whose depression does not respond fully to a single antidepressant are sometimes prescribed augmentation drugs, most commonly low-dose atypical antipsychotics like quetiapine or aripiprazole. Atypical antipsychotics are well-known for causing weight gain and blood sugar problems at the higher doses used for psychotic disorders. The question is whether the low doses used alongside antidepressants carry the same risk.

A large study examining low-dose quetiapine initially found a slightly elevated rate of type 2 diabetes compared with SSRIs alone. But when the researchers accounted more carefully for differences between the groups, that increased risk essentially disappeared.¹⁴ The finding highlights an important point: people who need augmentation therapy tend to have more severe depression, more comorbidities, and more complicated health profiles. Disentangling the drug’s effect from the patient’s baseline risk is genuinely difficult. If you are on a low-dose antipsychotic alongside your antidepressant, the metabolic risk is worth discussing with your prescriber but is not as alarming as the full-dose antipsychotic data might suggest.

How These Drugs Actually Affect Blood Sugar

There is no single pathway by which antidepressants raise blood sugar. Several mechanisms operate at once, and which ones dominate depends on the specific drug’s receptor profile.

Weight gain: The most straightforward route. Drugs that increase appetite or cause sedation lead to added body fat, which worsens insulin resistance over time. Mirtazapine and TCAs are the most common offenders.
Histamine and serotonin receptor blocking: Binding to histamine-1 and 5-HT2c receptors promotes hunger and reduces the body’s ability to regulate energy balance. Antidepressants with strong affinity at these sites show the most pronounced links to hyperglycemia.
Direct beta-cell effects: Some drugs impair the ability of insulin-producing cells to release insulin properly, as shown with fluoxetine in lab models.
Norepinephrine-driven glucose release: Drugs that increase norepinephrine activity can trigger the liver to release more glucose and reduce peripheral tissue sensitivity to insulin.
Stress-hormone axis changes: Depression itself ramps up cortisol production, which raises blood sugar. Some antidepressants help calm this axis, which may improve glucose control, while others do little to address it.

This multi-pathway picture explains why the same drug can appear beneficial in one study and harmful in another. A drug that helps beta cells in a test tube but also causes 10 pounds of weight gain over six months may produce a net increase in blood sugar despite a theoretically positive direct effect.

Separating the Drug Effect from Depression Itself

Depression is independently linked to higher diabetes risk, even in people who never take an antidepressant. People who are depressed tend to eat less carefully, exercise less, sleep poorly, and skip medical appointments. Depression also drives chronic inflammation and elevated cortisol, both of which worsen insulin resistance. A large meta-analysis acknowledged this tangled web of confounders and attempted to control for both body mass index and depression severity. The association between antidepressants and new diabetes held up even after those adjustments, but the researchers cautioned that residual confounding can never be fully ruled out.¹⁵

One particularly tricky confounder is residual depression symptoms. Someone whose depression score has technically improved but who still has fatigue, low motivation, and poor sleep may not meet criteria for a depressive episode, yet those lingering symptoms can reduce physical activity enough to affect blood sugar. That makes it hard to say whether rising blood sugar in the second year of antidepressant treatment is caused by the drug, the underlying condition, or the lifestyle that comes with partially treated depression.

This matters practically because the alternative to taking an antidepressant is often untreated depression, which is itself a metabolic risk factor. A narrative review noted that managing depression with antidepressants can improve glucose balance and insulin sensitivity, even though prolonged use may eventually raise diabetes risk.¹⁶ The net effect depends on which drug, at what dose, for how long, and in what patient.

Dose and Duration Make a Big Difference

One of the most consistent findings across studies is that higher doses and longer treatment durations increase the metabolic risk. The Japanese cohort study found that the hazard ratio for developing diabetes climbed steadily from about 1.27 for short-term low-dose use to 3.95 for long-term high-dose use.¹ The same study found that people who discontinued or reduced their antidepressant dose saw their HbA1c levels drop.¹

This does not mean you should abruptly stop or reduce your antidepressant to protect your blood sugar. Stopping antidepressants without medical guidance risks a depressive relapse, and the metabolic consequences of untreated depression may be worse than the drug’s effects. The practical takeaway is that periodic reassessment matters. If you have been on a high dose for years, your prescriber should be checking metabolic markers regularly and considering whether the dose is still appropriate.

Practical Monitoring for People on Antidepressants

A review aimed at primary care physicians recommended that all patients starting antidepressants get baseline measurements of weight, waist circumference, and metabolic markers like fasting glucose or HbA1c. Ongoing monitoring should then be tailored based on individual risk factors and whether weight gain has occurred.¹⁷

In practice, this often does not happen. Antidepressants are frequently managed by primary care rather than psychiatry, and metabolic monitoring is not built into the standard prescribing workflow the way it is for antipsychotics. If you are starting an antidepressant or have been on one for a while, it is reasonable to ask for a fasting glucose or HbA1c at your next visit, especially if you have a family history of diabetes, have gained weight since starting the medication, or are on a drug known to be metabolically unfavorable like a TCA or mirtazapine.

People who already have type 2 diabetes deserve special attention. Their blood sugar monitoring should pick up any drug-related changes relatively quickly, but the connection is not always obvious in real life. A slow upward drift in fasting glucose over several months might be attributed to diet or disease progression when the antidepressant is actually the new variable. Mentioning any recent medication changes to whoever manages your diabetes care can save months of chasing the wrong explanation.

MAO Inhibitors and the Opposite Problem

While most of the conversation centers on hyperglycemia, one older class of antidepressants can push blood sugar dangerously low. Nonselective hydrazine monoamine oxidase inhibitors like phenelzine have been associated with hypoglycemia and an increased rate of glucose disposal.¹¹ For people on diabetes medications that already lower blood sugar, adding phenelzine could create a risk of episodes where glucose drops too low. MAO inhibitors are rarely prescribed today because of their dietary restrictions and drug interaction profile, but they remain an option for treatment-resistant depression, and clinicians and patients should be aware of this unusual metabolic wrinkle.

1
Diabetes Care. Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes: A Large, Population-Based Cohort Study in Japan
2
PubMed Central. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review
3
PubMed. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice
4
PubMed. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports
5
PubMed Central. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports
6
JAMA Psychiatry. Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents
7
Scientific Reports. Selective serotonin reuptake inhibitor, fluoxetine, impairs E-cadherin-mediated cell adhesion and alters calcium homeostasis in pancreatic beta cells
8
PubMed Central. Metabolic Effects of Antidepressant Treatment
9
American Journal of Physiology-Endocrinology and Metabolism. Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats
10
Diabetes, Obesity and Metabolism. The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta‐cell mass and function in vitro
11
PubMed. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms
12
PubMed Central. Short Term Risk of Type 2 Diabetes in Patients Using Various Antidepressants Compared with Patients Using Fluoxetine
13
PubMed Central. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
14
JAMA Network Open. Association of Low-Dose Quetiapine and Diabetes
15
PLoS ONE. The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis
16
PubMed Central. Antidepressants and type 2 diabetes: highways to knowns and unknowns
17
PubMed. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians